Drug outfits doing better at posting trial data

According to an editorial in the New England Journal of Medicine, the number of trials posted at the NIH's site with incomplete data has dropped from 26 percent before 2006 to 8 percent in the first 11 months of last year. The increase in voluntary disclosure came after some blistering criticism that large pharma companies had been essentially hiding data that raised safety issues regarding its drugs. The better response, though, is unlikely to dull the appetite in Congress for new laws requiring public disclosure, especially after the Democrats gained control of both houses of Congress.

- here's the report on trial data from The Boston Globe

Related Articles:
Will pharma-bashing go to far? Editorial
Consumers, pharmaceutical companies differ on views of pharma industry. Release

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.